Related Experiment Videos
Intravesical suramin in the prevention of transitional cell carcinoma
S D Graham1, P Napalkov, A Oladele
1Department of Surgery, Emory University School of Medicine, Atlanta, Georgia.
Objectives:
To examine the effects of intravesical suramin on N-methyl-N-nitrosurea (MNU)-induced bladder tumors in Fischer 344 rats.
Methods:
Multiple cohorts of female rats received four biweekly intravesical instillations of MNU. A control group received no other treatment, the experimental group received 25 mg/kg intravesical suramin twice a week beginning at week 6.
Results:
After 18 weeks from the first instillation of MNU, 60% to 65% of control animals developed papillary transitional cell carcinoma, compared with only 0% to 10% of the suramin-treated animals (P = 0.01 to P = 0.0007). There was no local or systemic toxicity observed.
Conclusions:
Intravesical suramin is an effective chemopreventative therapy for transitional cell carcinoma in vivo with minimal toxicity.
Insights
Intravesical suramin effectively prevented bladder tumors in rats. This study shows suramin as a promising chemopreventative therapy for transitional cell carcinoma with minimal toxicity.
Area of Science:
- Oncology
- Urology
- Pharmacology
Background:
- N-methyl-N-nitrosurea (MNU) is a known carcinogen that induces bladder tumors.
- Transitional cell carcinoma (TCC) is a common type of bladder cancer.
- Chemoprevention strategies are crucial for managing and preventing cancer development.
Purpose of the Study:
- To investigate the efficacy of intravesical suramin in preventing MNU-induced bladder tumors in Fischer 344 rats.
- To assess the safety and toxicity profile of intravesical suramin in this model.
Main Methods:
- Female Fischer 344 rats were administered intravesical MNU to induce bladder tumors.
- Experimental groups received intravesical suramin (25 mg/kg) biweekly, starting at week 6.
- A control group received MNU without suramin treatment.
Main Results:
- A significant reduction in papillary transitional cell carcinoma incidence was observed in suramin-treated rats (0-10%) compared to controls (60-65%).
- Statistical significance was achieved (P = 0.01 to P = 0.0007).
- No local or systemic toxicity was detected in the suramin-treated group.
Conclusions:
- Intravesical suramin demonstrates significant chemopreventative efficacy against MNU-induced bladder cancer in vivo.
- Suramin is a well-tolerated therapeutic agent with minimal toxicity in this preclinical model.
- These findings support the potential of intravesical suramin as a chemopreventative therapy for transitional cell carcinoma.